Compare Stocks: KAPA, ATOS, PVCT, and ESLA

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATOS Atossa Genetics	$1.90 -7.3%	$2.42	$1.70 ▼ $19.35	$20.46M	1.27	48,325 shs	77,555 shs
ESLA Estrella Immunopharma	$0.48 +2.1%	$0.68	$0.46 ▼ $3.15	$20.49M	0.88	42,113 shs	27,798 shs
KAPA Kairos Pharma	$1.72 -2.8%	$2.01	$1.51 ▼ $9.59	$5.99M	1.48	99,201 shs	42,261 shs
PVCT Provectus Biopharmaceuticals	$0.05 -0.9%	$0.06	$0.04 ▼ $0.09	$23.11M	0.86	93,894 shs	126,689 shs

7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATOS Atossa Genetics	-5.96%	-14.58%	-23.51%	+9.04%	-83.44%
ESLA Estrella Immunopharma	-0.21%	-10.46%	-35.70%	-52.71%	-60.29%
KAPA Kairos Pharma	+2.31%	-2.21%	+1.88%	-27.76%	-78.93%
PVCT Provectus Biopharmaceuticals	+3.97%	-1.26%	-8.79%	-17.42%	-17.91%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATOS Atossa Genetics	$1.90 -7.3%	$2.42	$1.70 ▼ $19.35	$20.46M	1.27	48,325 shs	77,555 shs
ESLA Estrella Immunopharma	$0.48 +2.1%	$0.68	$0.46 ▼ $3.15	$20.49M	0.88	42,113 shs	27,798 shs
KAPA Kairos Pharma	$1.72 -2.8%	$2.01	$1.51 ▼ $9.59	$5.99M	1.48	99,201 shs	42,261 shs
PVCT Provectus Biopharmaceuticals	$0.05 -0.9%	$0.06	$0.04 ▼ $0.09	$23.11M	0.86	93,894 shs	126,689 shs

7 Stocks That Could Lead the Next Market Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATOS Atossa Genetics	-5.96%	-14.58%	-23.51%	+9.04%	-83.44%
ESLA Estrella Immunopharma	-0.21%	-10.46%	-35.70%	-52.71%	-60.29%
KAPA Kairos Pharma	+2.31%	-2.21%	+1.88%	-27.76%	-78.93%
PVCT Provectus Biopharmaceuticals	+3.97%	-1.26%	-8.79%	-17.42%	-17.91%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ATOS Atossa Genetics	2.20	Hold	$20.33	970.18% Upside
ESLA Estrella Immunopharma	2.00	Hold	$8.00	1,563.20% Upside
KAPA Kairos Pharma	3.00	Buy	$63.00	3,562.79% Upside
PVCT Provectus Biopharmaceuticals	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest KAPA, ATOS, PVCT, and ESLA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/24/2026	ESLA Estrella Immunopharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
9/8/2026	ATOS Atossa Genetics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
9/8/2026	ESLA Estrella Immunopharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/25/2026	ESLA Estrella Immunopharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/11/2026	ESLA Estrella Immunopharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/21/2026	ESLA Estrella Immunopharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/7/2026	ATOS Atossa Genetics	Rodman & Renshaw Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$12.00

(Data available from 9/25/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ATOS Atossa Genetics	N/A	N/A	N/A	N/A	$4.57 per share	N/A
ESLA Estrella Immunopharma	N/A	N/A	N/A	N/A	($0.27) per share	N/A
KAPA Kairos Pharma	N/A	N/A	N/A	N/A	$2.13 per share	N/A
PVCT Provectus Biopharmaceuticals	$340K	67.37	N/A	N/A	($0.02) per share	-2.73

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ATOS Atossa Genetics	-$34.77M	-$3.11	N/A	N/A	N/A	N/A	-102.99%	-85.78%	11/11/2026 (Estimated)
ESLA Estrella Immunopharma	-$13.06M	-$0.24	N/A	N/A	N/A	N/A	N/A	-328.72%	12/2/2026 (Estimated)
KAPA Kairos Pharma	-$5.45M	N/A	N/A	N/A	N/A	N/A	-98.77%	-93.61%	N/A
PVCT Provectus Biopharmaceuticals	-$5.43M	N/A	N/A	N/A	N/A	N/A	N/A	-599.37%	N/A

Latest KAPA, ATOS, PVCT, and ESLA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	ESLA Estrella Immunopharma	-$0.09	-$0.05	+$0.04	-$0.05	N/A	N/A
8/12/2026	Q2 2026	KAPA Kairos Pharma	N/A	-$0.42	N/A	-$0.42	N/A	N/A
8/7/2026	Q2 2026	ATOS Atossa Genetics	-$1.02	-$0.95	+$0.07	-$0.95	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ATOS Atossa Genetics	N/A	N/A	N/A	N/A	N/A
ESLA Estrella Immunopharma	N/A	N/A	N/A	N/A	N/A
KAPA Kairos Pharma	N/A	N/A	N/A	N/A	N/A
PVCT Provectus Biopharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ATOS Atossa Genetics	N/A	5.69	5.14
ESLA Estrella Immunopharma	N/A	0.20	0.20
KAPA Kairos Pharma	N/A	11.98	11.98
PVCT Provectus Biopharmaceuticals	N/A	0.18	0.18

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ATOS Atossa Genetics	12.74%
ESLA Estrella Immunopharma	0.35%
KAPA Kairos Pharma	N/A
PVCT Provectus Biopharmaceuticals	0.05%

Insider Ownership

Company	Insider Ownership
ATOS Atossa Genetics	9.80%
ESLA Estrella Immunopharma	5.80%
KAPA Kairos Pharma	31.90%
PVCT Provectus Biopharmaceuticals	20.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ATOS Atossa Genetics	14	9.98 million	9.00 million	Optionable
ESLA Estrella Immunopharma	N/A	43.50 million	40.98 million	Not Optionable
KAPA Kairos Pharma	1	3.39 million	2.31 million	N/A
PVCT Provectus Biopharmaceuticals	4	420.28 million	335.38 million	Not Optionable

KAPA, ATOS, PVCT, and ESLA Headlines

Recent News About These Companies

VisiRose Selected to Present RB-PDAT at ESCRS iNovation® Day 2026 Emerging Company Showcase

July 22, 2026 | globenewswire.com

Independent University of Lille Study Shows Rose Bengal Sodium Produces Opposing Mechanistic Effects at the Same Dose

July 7, 2026 | globenewswire.com

Provectus Biopharmaceuticals and VisiRose Announce U.S. Patent Award for Light-Independent Antibacterial Eye Drop Targeting Drug-Resistant Ocular Infections

June 30, 2026 | globenewswire.com

Provectus Biopharmaceuticals Launches Veripure™, an Open Science Program for Medical Research Access to PV-10 (rose bengal sodium)

June 25, 2026 | globenewswire.com

Provectus Shareholders Approve Reverse Stock Split Authority

June 22, 2026 | tipranks.com

Provectus Biopharmaceuticals, Inc. (PVCT) Shareholder/Analyst Call Transcript

June 18, 2026 | seekingalpha.com

Provectus Biopharmaceuticals Announces Investor Webinar for 2026 Annual Meeting of Stockholders

June 8, 2026 | globenewswire.com

Provectus Biopharmaceuticals Reports Oral PV-10 Anti-Tumor Activity in Preclinical Bladder Cancer Study; Long-Term Survivors Show Absence of Gross Bladder Tumor at Study End

May 18, 2026 | globenewswire.com

Bascom Palmer Eye Institute Presents Four Posters on Rose Bengal Photodynamic Antimicrobial Therapy at ARVO 2026, Advancing the Clinical Case for Provectus’s VisiRose ...

May 4, 2026 | markets.businessinsider.com

Bascom Palmer Eye Institute Presents Four Posters on Rose Bengal Photodynamic Antimicrobial Therapy at ARVO 2026, Advancing the Clinical Case for Provectus's VisiRose Subsidiary and Rose Bengal Sodium in Infectious Keratitis

May 4, 2026 | globenewswire.com

Provectus Biopharmaceuticals to Hold 2026 Annual Meeting of Stockholders at Perkins Place, Its Planned New Headquarters in Knoxville, Tennessee

April 20, 2026 | globenewswire.com

Provectus Biopharmaceuticals Highlights Preclinical Evidence of PV-10-Mediated Immune Modulation in Burn Wound Healing; Porcine Study Demonstrates Shift Toward Pro-Regenerative ...

April 2, 2026 | finance.yahoo.com

Provectus Biopharmaceuticals Highlights Preclinical Evidence of PV-10-Mediated Immune Modulation in Burn Wound Healing; Porcine Study Demonstrates Shift Toward Pro-Regenerative Tissue Environment

April 2, 2026 | globenewswire.com

Provectus: Q4 Earnings Snapshot

March 26, 2026 | nhregister.comN

Provectus Biopharmaceuticals Inc.

March 13, 2026 | barrons.com

Provectus Biopharmaceuticals Inc.

March 13, 2026 | barrons.com

Provectus Pharmaceuticals Extends Conversion Date for Preferred Stock

February 2, 2026 | tipranks.com

Provectus announces publication of preclinical research on PV-10

October 9, 2025 | msn.com

Provectus Biopharmaceuticals Positions PV-10 as a Differentiated Alternative to Traditional Vaccine Adjuvants; University of Calgary Research Highlights Novel STING-Pathway ...

October 9, 2025 | markets.businessinsider.com

Provectus Biopharmaceuticals Positions PV-10 as a Differentiated Alternative to Traditional Vaccine Adjuvants; University of Calgary Research Highlights Novel STING-Pathway Activation for Improving Hepatitis B Vaccine Efficacy

October 9, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

KAPA, ATOS, PVCT, and ESLA Company Descriptions

Atossa Genetics NASDAQ:ATOS

$1.90 -0.15 (-7.32%)

Closing price 04:00 PM Eastern

Extended Trading

$1.92 +0.02 (+1.05%)

As of 07:50 PM Eastern

Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It also develops immunotherapy/chimeric antigen receptor therapy programs. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.

Estrella Immunopharma NASDAQ:ESLA

$0.48 +0.01 (+2.12%)

Closing price 04:00 PM Eastern

Extended Trading

$0.48 0.00 (0.00%)

As of 06:20 PM Eastern

Estrella Immunopharma, Inc., a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. is based in EmeryVille, California.

Kairos Pharma NYSEAMERICAN:KAPA

$1.72 -0.05 (-2.82%)

Closing price 04:10 PM Eastern

Extended Trading

$1.72 +0.00 (+0.12%)

As of 07:50 PM Eastern

We are a clinical-stage biopharmaceutical company advancing therapeutics for cancer patients that are designed to overcome key hurdles in immune suppression and drug resistance. These therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer and glioblastoma. We are driven by innovative science to develop novel and transformative drug therapies to treat cancer. Our mission is to advance our portfolio of innovative therapeutics to transform the way cancer is treated. We have leveraged molecular insights to develop a new class of novel drugs that we expect will target drug resistance and checkpoints of immune suppression. “Checkpoints” refer to molecules on certain immune cells that need to be activated (or inactivated) to start an immune response. Our portfolio of seven drug candidates offers diversification and mitigates the overall exposure to many of the inherent risks of drug development. Our key patents are licensed from Cedars-Sinai Medical Center, the largest academic medical center in the Western United States, and Tracon Pharmaceuticals, Inc., a clinical stage public biopharmaceutical company based in California. The science underlying the patents was developed at Cedars-Sinai Medical Center and was licensed to us from this institution. The human immune system can tell the difference between normal cells in the body and those it sees as “foreign,” which allows it to focus an attack on the foreign cells while leaving the normal cells alone. To do this, our immune system uses checkpoints. Cancer cells can find ways to use these checkpoints to avoid being attacked by the immune system. We are developing small molecules that we believe can specifically target these central checkpoints. In addition, we are developing an activated T cell therapy that is designed to transform a patient’s T cells into killer activated T cells against cancerous stem cells. These activated T cells are induced to target several antigen targets on glioblastoma cancer stem cells, the initiators and propagators of glioblastoma tumors. In June 2021, Kairos acquired Enviro Therapeutics, Inc., a California corporation (“Enviro”), through a share exchange. Enviro’s shareholders exchanged 100% of the outstanding shares of Enviro for 6,000,000 shares of newly issued restricted shares of common stock of Kairos. After the closing, Enviro became a wholly owned subsidiary of Kairos. The acquisition allowed us to incorporate into our company Enviro’s advanced pipeline of drug candidates in Phase 1 and Phase 2 trials. The pipeline includes two therapeutic agents addressing what we believe to be significant unmet needs in the prostate and lung cancer markets and that we believe can help address cancer progression in those cancers that develop resistance to standard therapies. Our drug candidate portfolio currently consists of a pipeline of seven drug candidates, including KROS drugs, which are immunotherapeutics, and ENV antibodies, which are designed to reverse drug resistance that often results as a consequence of the use of cancer therapeutics. Our pipeline is summarized below: . Five pre-clinical or clinical-trial stage drug candidates developed by us and designed to target immune response, including KROS 101, 102, 201, 301, and 401, which are designed to reverse immunosuppression of T cells that is caused by cancer. - KROS 101 and 102 are small molecules that are agonist and antagonist for the GITR (glucocorticoid induced TNF-like receptor) ligand, which respectively promote and inhibit T cell growth and function. GITR is a checkpoint central to control the numbers of T cells of the immune system. These molecules are in the preclinical stage and are being developed for clinical trials. - KROS 201 is an autologous T cell therapy targeting cancer stem cells of glioblastoma. This therapy has received an IND from the FDA for clinical trial and is undergoing preparation for a Phase 1 clinical trial for patients with recurrent glioblastoma. - KROS 301 is a small molecule that targets the NF-ĸß pathway, a cancer growth and immune suppressive molecule in triple negative breast cancer. This molecule is in preclinical testing. - KROS 401 is a cyclic peptide which inhibits the IL-4 and IL-13 (cytokines that play a critical role in the suppression of T cells by macrophages at the site of the tumor) receptor and is designed to reverse the immunosuppression induced by macrophages in the tumor microenvironment. . Two therapeutic agents developed by our Enviro subsidiary and designed to increase anti-tumor response in conjunction with cancer therapies by addressing resistance to these agents. - ENV 105 is an antibody that targets CD105 / Endoglin which is expressed in tumor cells and surrounding cells as the tumor becomes resistant to therapeutics in prostate cancer and lung cancer. This therapy is being tested in a randomized multicenter Phase 2 trial for prostate cancer and a Phase 1 trial in lung cancer, both of which began enrolling patients in September 2023. ENV 105 has received an IND from the FDA. - ENV 205 is an antibody that targets mitochondrial DNA which is elevated as patients become resistant to chemotherapies. This therapy is in preclinical testing. As of the date of this prospectus, our product candidates have not been approved as safe or effective by the FDA or any other comparable foreign regulator. Kairos Pharma, Ltd. was originally incorporated on June 17, 2013 under the laws of the State of California as NanoGB13, Inc. We changed our name to “Kairos Pharma, Ltd.” on July 15, 2016. On May 10, 2023, we filed a certificate of conversion with the Secretary of State of the State of California and, on the same date, we also filed with the Secretary of State of the State of Delaware a certificate of conversion from a non-Delaware corporation to a Delaware corporation pursuant to the Delaware General Corporation Law. In addition, on May 10, 2023, we also filed a certificate of incorporation with the Secretary of State of the State of Delaware and became a Delaware corporation. Our registered corporate address is 2355 Westwood Blvd., #139, Los Angeles, California.

Provectus Biopharmaceuticals OTCMKTS:PVCT

$0.05 0.00 (-0.91%)

As of 03:59 PM Eastern

Provectus Biopharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing immunotherapy medicines based on halogenated xanthenes in the United States. The company's lead molecule is rose bengal sodium (RBS). Its clinical development programs include PV-10 for the treatment of stage III and IV melanoma and different types of liver cancers; PH-10 for the treatment of psoriasis and atopic dermatitis, and skin inflammation; and PV-305 for the treatment of infectious keratitis. It is also developing oral formulations for adult solid tumor cancers, as well as refractory and relapsed pediatric, and other blood cancers comprising leukemias; PV-10 for the treatment of relapsed and refractory pediatric solid tumor cancers; and other formulations for the treatment of cutaneous canine cancers and healing of full-thickness cutaneous wounds. In addition, the company develops oral and intranasal formulations for the treatment of severe acute respiratory syndrome coronavirus 2; gram-positive and gram-negative bacterial infections; oral bacterial infections; and fungal infections, as well as vertebrate development, wound healing, and tissue regrowth. It has collaboration agreement with Bascom Palmer Eye Institute; and University of Miami. The company was formerly known as Provectus Pharmaceuticals, Inc. and changed its name to Provectus Biopharmaceuticals, Inc. in December 2013. Provectus Biopharmaceuticals, Inc. was founded in 2002 and is based in Knoxville, Tennessee.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest KAPA, ATOS, PVCT, and ESLA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest KAPA, ATOS, PVCT, and ESLA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

KAPA, ATOS, PVCT, and ESLA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

KAPA, ATOS, PVCT, and ESLA Company Descriptions

Atossa Genetics NASDAQ:ATOS

Estrella Immunopharma NASDAQ:ESLA

Kairos Pharma NYSEAMERICAN:KAPA

Provectus Biopharmaceuticals OTCMKTS:PVCT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest KAPA, ATOS, PVCT, and ESLA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest KAPA, ATOS, PVCT, and ESLA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

KAPA, ATOS, PVCT, and ESLA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

KAPA, ATOS, PVCT, and ESLA Company Descriptions

Atossa Genetics NASDAQ:ATOS

Estrella Immunopharma NASDAQ:ESLA

Kairos Pharma NYSEAMERICAN:KAPA

Provectus Biopharmaceuticals OTCMKTS:PVCT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools